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Objective: To standardize the single nucleotide polymorphism array (SNPa) method in acute
myeloid  leukemia/myelodysplastic syndromes, and to identify the similarities and differ-
ences between the results of this method and karyotyping.
Methods: Twenty-two patients diagnosed with acute myeloid leukemia and three with
myelodysplastic syndromes were studied. The G-banding karyotyping and single nucleotide
polymorphism array analysis (CytoScan® HD) were performed using cells from bone marrow,
DNA extracted from mononuclear cells from bone marrow and buccal cells (BC).
Results: The mean age of the patients studied was 54 years old, and the median age was
55  years (range: 28–93). Twelve (48%) were male and 13 (52%) female. Ten patients showed
abnormal karyotypes (40.0%), 11 normal (44.0%) and four had no mitosis (16.0%). Regarding
the  results of bone marrow single nucleotide polymorphism array analysis: 17 were abnor-
mal  (68.0%) and eight were normal (32.0%). Comparing the two methods, karyotyping
identiﬁed a total of 17 alterations (8 deletions/losses, 7 trissomies/gains, and 2 transloca-
tions)  and single nucleotide polymorphism array analysis identiﬁed a total of 42 alterations
(17 losses, 16 gains and 9 copy-neutral loss of heterozygosity).
Conclusion: It is possible to standardize single nucleotide polymorphism array analysis in
acute myeloid leukemia/myelodysplastic syndromes and compare the results with the
abnormalities detected by karyotyping. Single nucleotide polymorphism array analysis
increased the detection rate of abnormalities compared to karyotyping and also identiﬁed
a  new set of abnormalities that deserve further investigation in future studies.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
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cute myeloid leukemia (AML) is a group of clonal disorders
esulting from acquired somatic genetic lesions accumu-
ated in hematopoietic progenitors in a step-wise fashion
hroughout life. The mutations give rise to a malignant
ematopoietic clone; malignant hematopoiesis subsequently
uppresses normal hematopoiesis.1,2
The myelodysplastic syndromes (MDS) are a group of
lonal hematopoietic stem cell disorders involving cytogenetic
hanges, and gene mutations that occur in a multistep pro-
ess, with widespread gene hypermethylation at advanced
tages. MDS  are characterized by ineffective hematopoiesis
eading to blood cytopenias or, in some cases, evolution to
ML.3
The detection of chromosomal abnormalities in AML/MDS
upports the diagnosis, classiﬁcation, prognostic stratiﬁ-
ation, therapy option, treatment monitoring and better
nderstanding of the disease’s biology.3,4 The consequence
f chromosomal investigations is major advances in the
reatment and survival of patients. However, about 50% of
ML/MDS have either normal karyotypes or non-recurrent
hromosomal abnormalities, which prevents a better char-
cterization of the disease.5,6 Therefore, an increased
bnormality detection rate by other methods and improved
nderstanding of pathogenesis are urgently needed.1,7,8
In this context, the single nucleotide polymorphism array
SNPa) method, also referred to as molecular karyotyping,
s a sensitive technology used to perform high-resolution
enome-wide DNA copy number analysis and to detect
egmental regions of homozygosity, known as regions of copy-
eutral loss of heterozygosity (CN-LOH).2,9
SNPa analysis uses millions of markers (probes com-
rise 25-mer oligonucleotides) across the entire human
enome.10 There are two types of probes: non-polymorphic
robes, used only for assessing copy number variations (CNV)
Figure 1A), and polymorphic probes, used to assess genotypes
Figure 1B).11 For copy number analysis, patient DNA labeled
ith a ﬂuorochrome provides signal intensity that, when com-
ared to a set of reference DNAs, indicates whether there is a
igure 1 – Affymetrix® Chromosome Analysis Suite image show
 normal copy number (purple line CN: 2.00). The information on
B) Allele peaks representing a normal genotype with AA, AB and
enotype is from polymorphic probes.2 0 1 5;3 7(1):48–54 49
gain or loss of genetic material. For genotype analysis, a single
nucleotide polymorphism (SNP) has a single base pair substi-
tution (A, T, C, or G) of one nucleotide to another, then, the
alleles corresponding to the nucleotide base changes are arbi-
trarily given the designation allele A and allele B (polymorphic
probes) and reveal which of the genotypes (for example, AA,
BB or AB) is present.12
In order to better deﬁne the genetic abnormalities, the
objective of this study was to identify the similarities and
differences between SNPa analysis and karyotyping in 25
AML/MDS cases at diagnosis.
Methods
Case  selection
Twenty-ﬁve patients with AML (n = 22, non-acute promyelo-
cytic leukemia) and MDS (n = 3) diagnosed according to WHO
criteria at the Escola Paulista de Medicina, Universidade Fed-
eral de São Paulo (UNIFESP) from March 2012 to January 2014
were studied.4 Bone marrow (BM) aspirate was collected at
diagnosis from all patients.
At the same time, buccal cells (BC) were also collected
(DNA-SALTMOasis Diagnostics®) to distinguish clonal abnor-
malities from constitutional ﬁndings.13,14
The study was approved by the Ethics Committees of
UNIFESP and Grupo Fleury and was conducted in accor-
dance with the Helsinki Declaration as revised in 2008.
All patients gave informed consent prior to entering the
study.
Karyotyping
The karyotyping was performed for all BM samples at the time
of initial diagnosis and conventional cytogenetic analyses
of 24–48 h cultures were performed on bone marrow aspi-
rates using standard techniques. The karyotype results were
described according to the International System for Human
Cytogenetic Nomenclature 2009.15–17 Whenever possible, at
least 20 metaphases were analyzed.17
ing normal chromosome 4. (A) Smooth signal representing
 copy number variations is from non-polymorphic probes.
 BB alleles (three purple lines). Information on the
moter. 2 0 1 5;3 7(1):48–54
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Figure 2 – Results of karyotyping (abnormal: 10 patients,
normal: 11 patients and no results: 4 patients) and bone
marrow single nucleotide polymorphism array analysis
(SNPa; abnormal: 17 patients and normal: 8 patients).
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Figure 3 – Frequency of abnormalities detected by
karyotyping only: 4 (8.7%), by bone marrow single
nucleotide polymorphism array (SNPa) analysis only: 2950  rev bras hematol he
Single  nucleotide  polymorphism  array  analysis
SNPa analysis was performed for all samples (BM and BC).13
Mononuclear cells from BM were separated (Ficoll method)
and DNA was extracted from these cells as well as
from BC (Nucleic Acid and Protein Puriﬁcation kit from
Marcherey-Nagel®).14,18 DNA (250 ng) was digested, ampliﬁed,
puriﬁed, fragmented, labeled and hybridized using Affymetrix
CytoScan® HD Array GeneChip; CEL ﬁles were created using
the GeneChip® System 3000 7G according to the manufac-
turer’s instructions (Affymetrix). The CEL ﬁles were analyzed
using Chromosome Analysis Suite v2.0 (ChAS) software.19,20
Equipment, instrumentation, and methodologies emplo-
yed during the use of microarray platforms were calibrated,
monitored, and regularly maintained as appropriate. Positive
(Genomic DNA Control supplied by Affymetrix) and negative
controls (Low EDTA TE Buffer) were used to validate chip,
reagents, and instruments and every CytoScan® HD array has
internal quality control metrics used to determine pass/fail for
individual samples.21
Regions of CNV larger than 1 Mb  and CN-LOH larger than
10 Mb  identiﬁed by the ChAS Software or detected by visual
inspection, regardless of gene content, are denoted as true
aberrations, with the exception of those known to be normal
genomic variants (present in the Genomic Variants Database
[http://projects.tcag.ca/variation]) and/or found in constitu-
tional (BC) SNPa analysis.9,18,22,23
SNPa results of BC indicate the individual constitutional
genome. Thus, changes observed in BM and not found in BC
are indicative of acquired abnormalities and were considered
for evaluation.13
Results
The mean age of the patients was 54 years and the median age
was 55 years (range: 28–93). Twelve patients (48%) were male
and 13 (52%) were female.
Karyotyping and SNPa results are listed in Table 1.
Karyotype
Ten patients had abnormal karyotypes (40.0%), 11 normal
(44.0%) and four had no mitosis (16.0%) (Figure 2).
Karyotyping detected a total of 17 alterations (8 dele-
tions/losses, 7 trisomies/gains and 2 translocations) in the 25
cases (Figure 3).
Single  nucleotide  polymorphism  array
By BM SNPa analysis, 17 patients were abnormal (68.0%) and
eight normal (32.0%) (Figure 2) and by BC SNPa analysis, six
patients were abnormal (24.0%), 17 were normal (68.0%) and
two had no results (8.0%). The internal quality control of
Genechip failed for two samples.SNPa analysis detected a total of 42 alterations (17 losses,
16 gains and 9 CN-LOH) in the 25 cases (Figure 3).
The SNPa method detected all abnormalities found by kar-
yotype except for:(63.0%) and by both methods simultaneously: 13 (28.3%).
• polyploidy in Case 6;
• t(8;21) in Cases 19 and 20;
• ?del(3)(q26) in Case 22.
On the other hand, SNPa detected many  abnormalities not
found by karyotyping:
• CN-LOH in 3p21.31p21.2, −7, +8, loss in 12p13.33p12.3,
12p12.1p11.22, 12q22q23.3, −16 and −Y in Case 1;
• mosaic gain in 1q31.1q44 and 6q22.33q27, +8 mosaic loss
in 2q24.2q37.3, 5q15.q31.1, 5q31.3q32, 5q33.1q35.1 and CN-
LOH in 16q21q24.3 in Case 6;
• CN-LOH in 9p24.3p13.3 in Case 13 (Figure 4A);
• +8 in Case 14;
• mosaic gain in 19p13.3p13.11 and 19q13.31q13.33 in Case 17;
• gain in 6q27 in Case 22;
• CN-LOH in 4q31.21q34.3 and 12q23.1q24.11 in Case 23;
• CN-LOH in 6q13q14.3 and 21q21.1q22.3 in Case 24.The following abnormalities were found by SNPa analysis
in cases that karyotyping had no mitosis:
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Table 1 – Karyotyping and single nucleotide polymorphism array results.
Case Diagnosis Karyotyping SNPa (BM) SNPa (BC)
1 AML 46,XY[20] Normal Normal
2 AML 46,XY,del(5)(q15q33),del(17)(p11.2)[16]/46,XY[4] 3p21.31p21.2 CN-LOH; 5q21.1q35.3
loss (CN: 1.00); −7; +8;
12p13.33p12.3 loss (CN: 1.00);
12p12.1p11.22 loss (CN: 1.00);
12q22q23.3 loss (CN: 1.00); −16;
17p13.3p11.2 mosaic loss (CN:
1.50); −Y
DGVa
3 AML 46,XX[20] Normal Normal
4 AML 46,XX[20] Normal Normal
5 AML 47,XY,+4[10] +4 Normal
6 AML 92,XXYY[20] 1q31.1q44 mosaic gain (CN: 2.41);
2q24.2q37.3 mosaic loss (CN: 1.48);
5q15q31.1 mosaic loss (CN: 1.72);
5q31.3q32 mosaic loss (CN: 1.76);
5q33.1q35.1 mosaic loss (CN: 1.73);
6q22.33q27 mosaic gain (CN: 2.31);
+8; 16q21q24.3 CN-LOH
Normal
7 AML 47,XX,+8[17]/46,XX[3] 8 mosaic gain (CN: 2.65) DGVa
8 AML 46,XY,del(9)(q21)[20] 9q21.11q22.33 loss (CN: 1.00) 9q21.11q22.33 loss (CN:
1.00)
9 AML No mitoses +8; 17q21.2q25.3 CN-LOH Normal
10 AML No mitoses 9 mosaic gain (CN: 2.69) 9 mosaic gain (CN: 2.48)
11 AML No mitoses Normal Normal
12 AML 46,XY[15] Normal Normal
13 AML 48,XX,+8,+21[11]/46,XX[1] 8 mosaic gain (CN: 2.57); 21 mosaic
gain (CN: 2.54); 9p24.3p13.3
CN-LOH
Normal
14 AML 46,XX[10] +8 8 mosaic gain (CN: 2.93)
15 AML No mitoses 1q21.1q44 gain (CN: 3.00);
5q15.33q11.2 mosaic gain (CN:
2.39)
Normal
16 AML 46,XX[14] Normal Normal
17 AML 46,XX[20] 19p13.3p13.11 mosaic gain (CN:
2.31); 19q13.31q13.33 mosaic gain
(CN: 2.22)
Normal
18 AML 46,XY[20] Normal Normal
19 AML 46,XY,t(8;21)(q22;q22)[20]/47,XY,+8,t(8;21)(q22;q22)
[3]/46,X,−Y,+8,t(8;21)(q22;q22)[2]
+8;  −Y Normal
20 AML 45,X,t(8;21)(q22;q22)[5]/46,XX[5] X mosaic loss (CN: 1.25) Normal
21 AML 46,XX[15] Normal Normal
22 AML 48,XY,?del(3)(q26),del(11)(q23),+i(21)(q10)x2[cp20] 6q27 gain (CN: 3.00); 11q23.3q25
loss (CN: 1.00); 21q11.2q22.3 gain
(CN: 4.75)
Normal
23 MDS 46,XX[20] 4q31.21q34.3 CN-LOH;
12q23.1q24.11 CN-LOH
4q31.21q34.3 CN-LOH;
12q23.1q24.11 CN-LOH
24 MDS 46,XY[15] 6q13q14.3 CN-LOH; 21q21.1q22.3
CN-LOH
6q13q14.3 CN-LOH
25 MDS 46,XXdel(5)(q13q33)[19]/46,XX[1] 5q15q33.2 loss (CN:1.00) 5q15q33.2 loss (CN:1.00)
SNPa: single nucleotide polymorphism array; BM: bone marrow; BC: buccal cells; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome;
CN: copy number; LOH: loss of heterozygosity; DGV: genomic variants database.
Loss: CN < 2.00; gain: CN > 2.00; normal: CN = 2.00. Y and X for male: normal: CN = 1.00.
a BC SNPa (constitutional) was done but failed in the quality control metrics, in these cases the DGV data base was used to validate the ﬁndings
in BM SNPa test.
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Figure 4 – Affymetrix® Chromosome Analysis Suite Image. (A) Paired analysis (Buccal cell and bone marrow single
nucleotide polymorphism array analysis) of chromosome 9 showing copy-neutral loss of heterozygosity (CN-LOH) only in
bone marrow. (B) Paired analysis (Buccal cell and bone marrow single nucleotide polymorphism array analysis) of
w.chromosome 1 showing 1q21.1q44 gain only in bone marro
• +8 and CN-LOH in 17q21.2q25.3 in Case 9;
• mosaic gain in all chromosome 9 in Case 10;
• gain in 1q21.1q44, mosaic gain in 5q15.33q11.2 in Case 15
(Figure 4B).Discussion
Cytogenetic abnormalities identiﬁed by karyotyping remain
the most important prognostic factor in AML.2,24Molecular karyotyping of these cases by SNPa analysis
demonstrated additional information regarding microscopic,
submicroscopic, and CN-LOH alterations; the combination of
SNPa analysis with karyotyping improves the detection rate
for abnormalities.23
Clearly, the SNPa method does not replace karyotyping as
it cannot detect balanced translocations that are relevant to
the diagnosis and management of a variety of hematopoietic
malignancies.11
In general, cytogenetic abnormalities observed in MDS,
unlike AML, are losses or gains of genetic material. Despite
oter. 
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he small number of MDS  patients included in this study (three
ases), all had abnormalities detected by SNPa analysis, while
nly one had an abnormal karyotype.
CN-LOH regions were found in Cases 6, 9, 13, 23 and 24 (20%
f cases). This abnormality represents an important mech-
nism by which point mutations and other micro lesions
an be established in an homozygous state detectable by
NPa analysis.13,25 CN-LOH is thought to be positively selected
uring clonal evolution because it can result in homozy-
osity for a mutation in one allele of a tumor suppressor
ene or oncogene, together with the loss of the wild-type
llele.13,26
Constitutional SNPa analysis (BC) was done in all cases in
rder to avoid false discoveries by comparing with the ﬁndings
or BM (Figure 4).13,18 In Case 23 two regions of constitu-
ional CN-LOH were found in 4q31.21q34.3 and 12q23.1q24.11.
n Case 24 one region of constitutional CN-LOH was found
n 6q13q14.3. Therefore, the interpretation of these cases
s that the abnormalities were not acquired, but constitu-
ional.
In four cases, the same alteration was found both by BM
nd BC SNPa analysis (constitutional). The alterations found
y BC SNPa  analysis in Cases 10 (mosaic gain in chromosome 9)
nd 14 (mosaic gain in chromosome 8) were present at a lower
evel than by the BM SNPa analysis, thus suggesting that the
C might have been contaminated with blood at the time of
ollection, though these changes might have been diluted in
C.13
In Cases 8 (loss in 9q21.11q22.33) and 25 (loss in 5q15q33.2),
he alterations found in the BC SNPa analysis were seen by
aryotyping and interpreted as an acquired alteration because
n Case 8 this deletion would result in constitutional dimor-
hism or related syndrome, while in Case 25 the clone was
etected by karyotyping along with normal cells. Supporting
his interpretation, beyond the scope of this work, we  per-
ormed SNPa analysis in Case 8 after induction therapy and
he proportion of the change (CNV) was lower, thereby sug-
esting that this abnormality was affected by chemotherapy.
ith this evidence, we  consider these two abnormalities as
cquired.
The quality control metrics in the constitutional (BC) SNPa
nalysis failed in Cases 2 and 7 and in these cases we used the
enomic Variants Database to validate the ﬁndings of the BM
NPa analysis.27 Possibly, the failure was due to poor quality
NA from BC.
In Cases 2 and 14, after SNPa analysis, some chromosomal
bnormalities (−7, +8, −16 and −Y) were found in sporadic
etaphases during the karyotyping reanalysis, but had not
nitially been described because they did not meet the crite-
ion to be considered as a cytogenetic clone,15 that is, more
han three cells with the same numerical change or two cells
ith the same rearrangement.28
The application of the SNPa technique has been largely
imited to exploratory research on cancer genetics. However,
iven its excellent performance in detecting genetic abnor-
alities in cancer, its application in clinical onco-hematology
ould be a logical step to attempt to establish better man-
11,29gement of cancer patients. The redundancy of tests is
eneﬁcial for comprehensive and indistinct characterization
f the disease.2 0 1 5;3 7(1):48–54 53
SNPa analysis may add value to karyotyping-non-
informative results and occasionally reveal cryptic abnormal-
ities not recognized by karyotyping.23 However, SNPa analysis
should be viewed as a complimentary tool. Some abnormali-
ties detected by SNPa analysis and not always recognized by
karyotyping are not yet included in classiﬁcation and progno-
sis criteria.30
Notwithstanding the progress in this area, SNPa tests have
not been studied to their full potential and many  questions
remain to be answered; for instance:
• In which situation could SNPa be performed in peripheral
blood samples and would the test offer the same informa-
tion as for marrow samples?
• Do abnormalities found only by SNPa analysis present the
same prognostic value as karyotyping?
• Should abnormal karyotypes also be investigated by SNPa
in order to amplify the detection of aberrations?
• Should treatment options targeting speciﬁc chromosomal
abnormalities be investigated by SNPa  analysis before
introducing the drug?
• Which SNPa results would drive a treatment change?
• What additional costs are acceptable in order to obtain bet-
ter treatment deﬁnition?
Conclusion
In summary, SNPa analysis was standardized in AML/MDS
and results were compared with the abnormalities detected
by karyotyping. SNPa analysis increased the detection rate of
abnormalities compared to karyotyping and also identiﬁed a
new set of abnormalities that should be further investigated
in future studies.
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